A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This will be a multi-institution, single-arm, open-label, phase I/II trial. Eligible patients
will have pathologically-proven T1b-3b, N0/1, M0 epithelial carcinoma of the cervix. We
hypothesize that sorafenib in combination with chemotherapy and radiotherapy may have
anti-tumor activity in patients with cervical cancer. Sorafenib has not previously been
combined with conventional RT-CT to treat cervix cancer.